Innate Pharma S.A. (IPHA) vs Nuvalent Inc (NUVL)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| IPHA | NUVL | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| Size band | SMALL | MID |
| Listing | Nasdaq GS | Nasdaq GM |
| Country | France | United States |
| Theme | oncology | oncology |
| Price and returns | ||
| Last close | $1.46 | $123.96 |
| Return · 1 week | 0.00% | 0.00% |
| Return · 1 month | −14.12% | 0.00% |
| Return · 3 months | −13.10% | 0.00% |
| Return · year to date | −19.78% | +22.93% |
| Return · 1 year | −38.66% | +26.87% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −46.13% | −0.02% |
| 52-week high | $2.71 | $123.99 |
| 52-week low | $1.17 | $87.30 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $163.08M | $9.79B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $45.84K | $149.69M |
| Employees | 120 | 234 |
| Valuation | ||
| Price to earnings · trailing | n/a (negative earnings) | n/a (negative earnings) |
| Price to earnings · forward | n/a (negative forward earnings) | n/a (negative forward earnings) |
| Price to sales | 18.45× | — |
| Price to book | n/a (negative book value) | 8.33× |
| Enterprise value to EBITDA | n/a (negative EBITDA) | — |
| Enterprise value to revenue | 15.47× | — |
| Earnings per share · trailing | -0.59 | -6.06 |
| Profitability | ||
| Operating margin | −335.71% | 0.00% |
| Profit margin | −483.85% | — |
| Return on equity | — | −41.19% |
| Return on assets | −46.60% | −22.51% |
| Growth | ||
| Revenue growth | +16.50% | — |
| Balance sheet and payout | ||
| Current ratio | 0.60 | 16.14 |
| Dividend yield | 0.00% | — |
| Payout ratio | 0.00% | 0.00% |
| Trend and volatility | ||
| RSI · 14 | 39.14 | — |
| ADX · 14 | 8.58 | — |
| 50-day average | $1.82 | — |
| 200-day average | $1.72 | — |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 7.05% | — |
The full IPHA analysis
Everything this table leaves out for Innate Pharma S.A.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the IPHA argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full IPHA analysisThe full NUVL analysis
Everything this table leaves out for Nuvalent Inc: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the NUVL argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full NUVL analysis